A lab technician inspects stuffed vials of investigational coronavirus illness (COVID-19) therapy drug remdesivir at a Gilead Sciences facility in La Verne, California.
Gilead Sciences Inc | Reuters
Gilead Sciences will purchase biopharmaceutical firm Immunomedics Inc. for $21 billion, a deal that may broaden Gilead’s availability of most cancers remedies, the company announced on Sunday.
Gilead will purchase Immunomedics for $88 per share in money. The transcation is anticipated to shut within the fourth quarter of 2020, in line with the assertion.
That is breaking information. Please examine again for updates.
